Advertisement

Topics

Latest Immunization NewsRSS

08:21 EST 14th December 2017 | BioPortfolio

Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Data Published in New England Journal of Medicine Demonstrate the Vaccine’s Immunogenicity

Pfizer Inc. (NYSE: PFE) today announced that detailed results from two pivotal Phase 3 studies of TRUMENBA® (Meningococcal Group B Vaccine) were published in the New England Journal of Medicine (NEJM). Data from both studies demonstrated that TRUMENBA, as a three-dose series, elicits a protective immune response against diverse meningococcal group B (Men...

Your NEJM Group Today: Sexual Harassment in Medicine / Bivalent Meningococcal B Vaccine / NYC Primary Care Opportunity

Here's what we chose for you from NEJM Group today: New England Journal of Medicine: Perspective: A physician and researcher makes the case that sexual...

Zika virus, not vaccine or insecticide, linked to birth defects in Brazil

This study is the first evidence that neither insecticides nor vaccines were culprits in the alarming number of babies born with microcephaly.

Sanofi Exec Forced to Apologize During Dengue Vaccine Inquiry

The French executive made the public apology after he was castigated by SAGIP Rep. Rodante Marcoleta for his company’s “insensitivity” to the concerns of the Filipino public.

Human medicines European public assessment report (EPAR): Prepandrix, prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted), Revision: 12, Authorised

Zoetis Launches Vanguard® CIV H3N2/H3N8 Vaccine for Canine Influenza Virus

Zoetis today announced the launch of Vanguard® CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus (CIV) portfolio. The new bivalent vaccine helps protect dogs against two strains of the virus known to be circulating in the U.S., CIV H3N2 and CIV H3N8. CIV is a severe and highly contagious respiratory infection that has caused many...

Veterinary medicine European public assessment report (EPAR): Aftovaxpur DOE, Foot-and-mouth disease vaccine (inactivated) (multistrain: 1-3 strains out of set of 8), Revision: 3, Authorised

Single-Dose Vaccine Could Provide Faster Protection in Cholera Epidemics

High-dose cholera vaccine developed by UMSOM scientists shows promise for controlling outbreaks

Sanofi Investors Crave for a Large Acquisition, Drug News

The drugmaker held an “innovation day” to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine.

Vaccine Efficacy Questionable Against Predominant Flu Virus

Flu shot could still keep you out of the hospital -- or the morgue.

Medical workers: Vaccinate yourselves first

Just under half of health care workers do not get their annual flu vaccine. Some of these workers contract the flu and unknowingly transfer it to their sick hospitalized patients, and in some cases, because of them passing the flu along, those patients die.   We know the most important reason for health care workers to […]

STAT Plus: Pharmalittle: Sanofi spars with Philippines over dengue vaccine; Niacor rises 809 percent

Avondale Pharmaceuticals raised the price of Niacor, a prescription version of Niacin, by 809 percent last month.

Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence

Takes Control of Full U.S. Marketing and Distribution Rights to IXIARO® Vaccine for Protection Against Japanese Encephalitis Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, today announced that its subsidiary Intercell USA, Inc. has formally changed its name to Valneva USA, Inc. (V...

Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines

Sanofi's vaccine worsens, rather than prevents, future dengue infections in some patients. The company vaccinated 830,000 children in the Philippines, where lawmakers now demand an accounting.

Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing

Proceeds will be used to progress lead development programs through Proof-of-Concept clinical trials Vienna, Austria, 11 December 2017 - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, today announced that it has raised $59.6 million (€50.0 million) in an overs...

      Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing

Proceeds will be used to progress lead development programs through Proof-of-Concept clinical trials Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, today announced that it has raised $59.6 million (€50.0 million) in an over...

PanProvincial Vaccine Enterprise Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 28112017] Prices from USD $250

SummaryPanProvincial Vaccine Enterprise Inc PREVENT is a national vaccine commercialization consortium that specializes in research and development of vaccines for infectious diseases. The institute develops vaccines for infectious disease, group A streptococcus vaccine, chlamydia vaccine, influenzaPAL vaccine, RSVP3 vaccine and CWD vaccine. It discovers vaccine through preclinical to Phase l and ...

US flu season off to an early start; widespread in 7 states

In this Friday, Sept. 22, 2017 file photo, a flu vaccine injection is administered at the Brownsville Events Center by a pharmacist in Brownsville, Texas.

Rite Aid advises consumers get their flu shot in first Facebook live event

Michael JohnsenRite Aid is offering three types of flu vaccines: a quadrivalent flu vaccine which offers protection against four strains of the flu; the standard trivalent vaccine; and FLUAD, a trivalent vaccine. read more

Pending EC decision: Suvaxyn Circo, porcine circovirus vaccine (inactivated, recombinant), Opinion date: 07-Dec-2017

Philippines Wants Money Back From Sanofi For Dengue Vaccine

NewsThe Philippine government will demand a $69.5 million refund from Sanofi Pasteur and look at possible legal action after a study showed the vaccine used in a dengue immunization program could expose some people to severe illness.

Uganda Controls Deadly Marburg Fever Outbreak, WHO Says

NewsThree people died during the outbreak in eastern Uganda near the Kenya border. There is no drug or vaccine for Marburg, which belongs to the same family as Ebola.

Veterinary medicine European public assessment report (EPAR): Bovilis Blue-8, bluetongue virus vaccine, serotype 8 (inactivated), Revision: 0, Authorised

Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China

Generex to receive a $700,000 USD up-front license fee; deal includes milestone payments and royalties Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (

Anti-GMO group March Against Monsanto promotes, profits from anti-vaccine ads

Quick Search
Advertisement
 

review and buy Immunization market research data and corporate reports here